Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.57 |
| ▸ | NPC1 | O15118 | 1/20 | 0.57 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.52 |
| ▸ | CA9 | Q16790 | 2/20 | 0.52 |
| ▸ | SIGMAR1 | Q99720 | 3/20 | 0.50 |
| ▸ | MAPT | P10636 | 4/20 | 0.49 |
| ▸ | TP53 | P04637 | 2/20 | 0.49 |
| ▸ | POLB | P06746 | 1/20 | 0.49 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6769718 | 0.88 | PDE4D (0.53) | KDM4ENPC1KMT2AGAACA9 | |
| SCHEMBL3299372 | 0.85 | KMT2A (0.68) | KMT2AGAACA9MAPTTP53 | |
| SCHEMBL18017546 | 0.84 | KMT2A (0.57) | KDM4ENPC1KMT2AGAACA9 | |
| SCHEMBL6763715 | 0.83 | CA9 (0.61) | KMT2AGAACA9MAPTTP53 | |
| SCHEMBL1877549 | 0.82 | TP53 (0.63) | KDM4EKMT2AGAACA9MAPT | |
| SCHEMBL20680840 | 0.81 | MAOA (0.46) | KMT2AGAACA9MAPT | |
| SCHEMBL30534855 | 0.81 | MAOA (0.46) | KMT2AGAACA9MAPT | |
| SCHEMBL1738619 | 0.81 | NOTUM (0.60) | KMT2AGAASIGMAR1MAPTTP53 | |
| SCHEMBL5340205 | 0.80 | CHRNA7 (0.61) | KDM4ENPC1KMT2AGAACA9 | |
| SCHEMBL18865871 | 0.80 | KMT2A (0.52) | KMT2AGAACA9MAPTTP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2576543-B1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2016-12-21 | — | — | EP | disclosed |
| EP-2576543-B1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | ESTEVE LABOR DR (ES) | 2016-12-21 | — | — | EP | disclosed |
| US-9181195-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-9181195-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-9181195-B2 | Sigma receptor inhibitors | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2015-11-10 | — | — | US | disclosed |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2013-06-20 | — | — | US | disclosed |
| EP-2576543-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | Laboratorios del Dr. Esteve S.A. (ES) | 2013-04-10 | — | — | EP | disclosed |
| EP-2395003-A1 | Pyrazole compounds as sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-12-14 | — | — | EP | disclosed |
| EP-2395003-A1 | Pyrazole compounds as sigma receptor inhibitors | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2011-12-14 | — | — | EP | disclosed |
| WO-2011147910-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| WO-2011147910-A1 | PYRAZOLE COMPOUNDS AS SIGMA RECEPTOR INHIBITORS | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2011-12-01 | — | — | WO | disclosed |
| US-20040116399-A1 | Inhibitors of factor Xa | MILLENNIUM PHARMACEUTICALS, INC. | 2004-06-17 | — | — | US | disclosed |
| US-6720317-B1 | 1-NAPHTH-2-YL-1H-PYRAZOLE-5-(4-AMIDINOPHENYL)CARBOXYAMIDE, MULTIPLY SUBSTITUTED; NON AMIDINO ANTICOAGULANTS; HEMOSTATIC AGENTS | MILLENNIUM PHARMACEUTICALS, INC. | 2004-04-13 | — | — | US | disclosed |
| US-6686368-B1 | Inhibitors of factor Xa | MILLENNIUM PAHRMACEUTICALS, INC. | 2004-02-03 | — | — | US | disclosed |
| US-6632815-B2 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2003-10-14 | — | — | US | disclosed |
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | MILLENNIUM PHARMACEUTICALS, INC. | 2002-07-11 | — | — | US | disclosed |
| EP-1216231-A2 | INHIBITORS OF FACTOR Xa | Millennium Pharmaceuticals, Inc. (US) | 2002-06-26 | — | — | EP | disclosed |
| WO-2001019798-A2 | INHIBITORS OF FACTOR Xa | COR THERAPEUTICS INC. (US) | 2001-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020091116-A1 | Show selectivity for factor Xa versus other proteases of coagulation or the fibrinolytic cascades | SERPINC1, TFPI, F2 | KDM4E 3940/4885NPC1 3613/4885KMT2A 4495/4885 |
| US-20130158029-A1 | SIGMA RECEPTOR INHIBITORS | SIGMAR1, TMEM97, OPRL1 | KDM4E 4507/4885NPC1 433/4885KMT2A 4002/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.